Study to Evaluate the Safety and Efficacy of Topical Minocycline FXFM244 in Impetigo Patients

Phase 2

Completed

• Conditions: Impetigo
• Interventions: Drug: Topical Minocycline Foam FXFM244

• Registration Number: NCT01171326
• Lead Sponsor: Vyne Therapeutics Inc.

Brief Summary

Impetigo is a common, highly infectious skin disease caused by bacterial infection and characterized by crusting skin lesions. It is most common in children, particularly children in unhealthy living conditions. In adults, it may follow other skin disorders. Impetigo is caused primarily by the bacteria Streptococcus pyogenes and/or Staphylococcus aureus, which can also be isolated from impetigo lesions.

This is a pilot phase II study to evaluate the tolerability and safety and to monitor the clinical efficacy of Topical Minocycline Foam FXFM244 in impetigo patients.

Detailed Description

A randomized, parallel-group, double (Investigator, patient) blind, comparative dose range finding clinical trial.

The study will involve two treatment groups. Eligible patients will be randomized to receive either FXFM244 - 1%, FXFM244 - 4% , in a blinded fashion. Patients will be treated twice daily for 7 days. Following the screening period and baseline visit, study subjects will return at days 3, 7 and 14. At each visit, patients will be evaluated via lesion count, global assessment tolerability and safety.

Study Timeline

• Study First Submitted: 2010-07-27
• Study First Submitted QC: 2010-07-27
• Study First Posted: 2010-07-28
• Study Start: 2010-08
• Status Verified: 2010-12
• Primary Completion: 2012-03
• Study Completion: 2012-04
• Last Update Submitted: 2013-12-09
• Last Update Posted: 2013-12-10

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 32

Inclusion Criteria

• Patients with clinical diagnosis of pure impetigo, impetigo contagiosa, or uncomplicated blistering impetigo
• Patients 2 years of age or older, and in general good health
• Patients with no less than two lesions and no more than seven lesions, area 0.5x0.5cm.
• No known medical conditions that, in the Investigator's opinion could interfere with study participation
• Patient / Patient's guardian (in the case of children) willing and able to comply with all requirement of the protocol
• Patient / Patient's guardian willing and able to give written informed consent prior to participation in the study

Read More

Exclusion Criteria

• Presence of skin diseases at or near the investigational area
• Immunosuppressed state or other serious systemic disease
• Signs and/or symptoms of systemic infection
• Presence of skin infection/disorder not amenable to topical antibacterial treatment only
• Presence of secondarily-infected animal/human bite
• Presence of secondarily infected burn wound
• Topical or systemic use of medicinal or other products before or during the study (oral or topical antibiotics, oral or topical corticosteroids and immuno modulators); or other drugs, which in the Investigators opinion could confound the evaluation of the effect of the study drugs
• Known or suspected hypersensitivity to Minocycline or any of the excipients in the study medication
• Participation in any other investigational drug study or use of (an) investigational drug(s) within the 30 days or 5 half-lives (whichever is longer) prior to randomization
• Patients previously enrolled/randomized in this study
• Use of another investigational drug within 30 days prior to entry into this study.
• Pregnant or lactating women.

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Topical Minocycline Foam FXFM244 - 1%	Topical Minocycline Foam FXFM244	Minocycline Foam FXFM244 - 1%
Topical Minocycline Foam FXFM244 - 4%	Topical Minocycline Foam FXFM244	Minocycline Foam FXFM244 - 4%

Primary Outcome Measures

Name	Time	Method
Decrease in lesion count	7 days

Secondary Outcome Measures

Name	Time	Method
The severity of the overall impetigo condition will be measured at baseline and at all follow-up visits. The severity will be assessed and graded based on the scales for Investigator's Global Assessment and bacteriological testing.	Days 3, 7 and 14

Trial Locations

Locations (1)

Lev Yasmin Clinic; 🇮🇱 Natanya, Israel